The Irish Bovine Tuberculosis (bTB) eradication programme operates under national legislation and fulfills OIE and EU trade requirements. Tuberculin purified protein derivative (PPD), a preparation obtained from the heat-treated products of growth and lysis of or (as appropriate), is critical to the diagnosis of tuberculosis (TB). Standardization of Tuberculin PPD potency, the relative activity in sensitized animals compared to a reference standard, is essential to underpin the reliability of certification for international trade and to ensure that disease eradication programmes are effective and efficient. A Bovine International Standard Tuberculin PPD (BIS) was established by the WHO in 1986 and is used to determine comparative potencies of Tuberculin PPDs. Ideally, Tuberculin PPD potency should be evaluated in the species in which the tuberculin will be used but due to practical difficulties in performing potency assays in cattle, for routine PPD production, they are usually assayed in guinea pigs. Low potency tuberculin PPD is less efficient and thus inferior for bTB diagnosis. Difficulties experienced in the Irish bTB eradication programme have included the supply of sub-standard potency, and thus inferior, bovine () Tuberculin PPD in the late 1970s. The purpose of this paper is to outline the critical role of Tuberculin PPD assays carried out on naturally infected tuberculous cattle, as required by the OIE and under EU legislation in the quality control for the Irish Bovine Eradication Programme. Such assays ensure that the Tuberculin PPD used meets the diagnostic sensitivity and specificity requirements to underpin a successful national eradication programme.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779688 | PMC |
http://dx.doi.org/10.3389/fvets.2019.00328 | DOI Listing |
BMC Infect Dis
December 2024
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, PR China.
Background: This study aimed to evaluate the diagnostic performance of ESAT6-CFP10 (EC) skin test in healthy population and determine the factors influencing the booster effect.
Methods: We conducted a randomized, double-blind, parallel controlled trial in healthy population. The experiment was divided into two stages.
Lancet Microbe
December 2024
Amsterdam University Medical Centres, Amsterdam, Netherlands; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
Background: Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development. We aimed to assess whether the effectiveness of the Bacillus Calmette-Guérin (BCG) vaccine for prevention of Mycobacterium tuberculosis infection was consistent with that for prevention of tuberculosis disease.
View Article and Find Full Text PDFBMC Infect Dis
December 2024
Department of Internal Medicine, Asokoro District Hospital, Abuja, Nigeria.
Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a leading cause of infection-related deaths worldwide. Children with underdeveloped immune systems are particularly vulnerable, experiencing symptoms akin to common childhood illnesses. Early diagnosis and treatment typically yield positive outcomes.
View Article and Find Full Text PDFOncol Rev
December 2024
Faculty of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Background: Latent tuberculosis (TB) can reactivate in immunocompromised individuals, such as cancer patients undergoing chemotherapy, leading to severe complications. Understanding the prevalence of latent TB in this high-risk group is crucial, especially in regions with moderate to high TB burdens.
Aim: This study aims to determine the prevalence of latent tuberculosis in cancer patients before chemotherapy and immunotherapy to guide preventive interventions and reduce the risk of TB reactivation.
N Engl J Med
December 2024
From the Faculty of Medicine and Health (G.J.F., P.N.Y., E.L.M., H.M.Y., E.G.-R., P.D.C., B.J.M., N.T.A.), the Sydney Infectious Diseases Institute (B.J.M.), and Sydney Medical School (H.M.Y.), University of Sydney, and Royal Prince Alfred Hospital, Sydney Local Health District (G.J.F.), Camperdown, NSW, the Woolcock Institute of Medical Research, Macquarie Park, NSW (G.J.F., N.C.B., P.N.Y., P.D.C., N.T.A., G.B.M.), the School of Clinical Medicine, University of New South Wales, Liverpool (F.L.G.), and the Department of Paediatrics, University of Melbourne (S.M.G.), and the Division of Global Health, Burnet Institute (G.B.M.), Melbourne, VIC - all in Australia; the University of Medicine and Pharmacy, Vietnam National University (N.V.N.), and the National Lung Hospital, Ba Dinh District (N.B.H., N.K.C.), Hanoi, and Pham Ngoc Thach Hospital, Ho Chi Minh City (N.H.L.) - all in Vietnam; the Departments of Medicine (A.B., O.S., M.A.B., D.M.), Epidemiology, Biostatistics, and Occupational Health (A.B., M.A.B., D.M.), and Microbiology and Immunology (O.S., M.A.B.), McGill University, Montreal; and Johns Hopkins University, Baltimore (D.W.D.).
Background: Prevention of drug-resistant tuberculosis is a global health priority. However, trials evaluating the effectiveness of treating infection among contacts of persons with drug-resistant tuberculosis are lacking.
Methods: We conducted a double-blind, randomized, controlled trial comparing 6 months of daily levofloxacin (weight-based doses) with placebo to treat infection.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!